Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Eur J Clin Pharmacol. 2013 Oct;69(10):1795-800. doi: 10.1007/s00228-013-1530-8. Epub 2013 Jun 9.
To investigate the dose and concentration dependency of CYP3A inhibition by ritonavir using the established limited sampling strategy with midazolam for CYP3A activity.
An open, fixed-sequence study was carried out in 12 healthy subjects. Single ascending doses of ritonavir (0.1-300 mg) were evaluated for CYP3A inhibition in two cohorts using midazolam as a marker substance.
Ritonavir administered as a single oral dose produced a dose-dependent CYP3A inhibition with an ID50 of 3.4 mg. Using the measured ritonavir concentrations an exposure-inhibition effect curve was established with an IC50 of 600 h pmol/L (AUC2-4). Over the ritonavir dose range studied non-linear exposure of ritonavir was observed.
Ritonavir shows a dose and concentration effect relationship of CYP3A inhibition. In addition, a proposed auto-inhibition of ritonavir metabolism resulted in a non-linear exposure of ritonavir with sub-proportional concentrations at low doses. A time-dependent CYP3A activity may result when inhibitors of CYP3A with short elimination half-lives are used.
利用已建立的咪达唑仑有限采样策略来研究利托那韦对 CYP3A 活性的抑制作用的剂量和浓度依赖性。
在 12 名健康受试者中进行了一项开放、固定序列的研究。使用咪达唑仑作为标记物,在两个队列中评估了利托那韦(0.1-300mg)的单递增剂量对 CYP3A 的抑制作用。
利托那韦单剂量口服给药产生剂量依赖性 CYP3A 抑制,ID50 为 3.4mg。使用测得的利托那韦浓度,建立了以 IC50 为 600 h pmol/L(AUC2-4)为特征的暴露-抑制效应曲线。在所研究的利托那韦剂量范围内,观察到非线性暴露利托那韦。
利托那韦显示出 CYP3A 抑制的剂量和浓度效应关系。此外,利托那韦代谢的自动抑制导致低剂量时非比例浓度的非线性暴露。当使用半衰期短的 CYP3A 抑制剂时,可能会导致 CYP3A 活性的时间依赖性。